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Abstract
Background: In view of the increasing availability of commercial internet-based Personal Genome Testing (PGT), this study
aimed to explore the reasons why people would consider taking such a test and how they would use the genetic risk
information provided.
Methodology/Principal Findings: A self-completion questionnaire assessing public awareness and interest in PGT and
motivational reasons for undergoing PGT was completed by 4,050 unselected adult volunteers from the UK-based TwinsUK
register, aged 17 to 91 (response rate 62%). Only 13% of respondents were aware of the existence of PGT. After reading a
brief summary about PGT, one in twenty participants (5%) were potentially interested at current prices (£250), however this
proportion rose to half (50%) if the test was free of charge. Nearly all respondents who were interested in free PGT reported
they would take the test to encourage them to adopt a healthier lifestyle if found to be at high genetic risk of a disease
(93%). Around 4 in 5 respondents would have the test to convey genetic risk information to their children and a similar
proportion felt that having a PGT would enable their doctor to monitor their health more closely. A TwinsUK research focus
group also indicated that consumers would consult their GP to help interpret results of PGT.
Conclusions/Significance: This hypothetical study suggests that increasing publicity and decreasing costs of PGT may lead
to increased uptake, driven in part by the general public’s desire to monitor and improve their health. Although the future
extent of the clinical utility of PGT is currently unknown, it is crucial that consumers are well informed about the current
limitations of PGT. Our results suggest that health professionals will inevitably be required to respond to individuals who
have undergone PGT. This has implications for health service providers regarding both cost and time.
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Introduction
Since autumn 2007, commercial companies have been offering
personal genomic testing (PGT) and disease risk calculations on
the internet. For fees starting at just a few hundred dollars these
companies look at more than a million variations (single nucleotide
polymorphisms, SNPs) across the genome to assess their
customers’ individual genetic predispositions to various diseases
(such as cardiovascular disease and diabetes), traits (like eye colour
and ear wax), carrier status, and drug sensitivities.
PGT differs from clinical genetic testing in three main ways.
First, instead of looking for the presence or absence of a single
mutation, PGT identifies a large number of susceptibility loci for a
wide variety of traits in order to calculate genetic risk. Second,
PGT focuses on complex diseases and traits, which are caused by
the interplay of various genetic and environmental factors, many
of which are as yet unknown or unexplored; resulting in low
predictive values [1–3]. An analysis of commercially available
direct-to consumer PGT published in autumn 2009 showed that
about 80% of reported relative risks were between 0.5 and 1.5. [4]
Another important difference between clinical genetic testing and
PGT is that consumers can purchase PGT without direct input
from medical professionals. PGT can be purchased and results
accessed directly through the internet [5]. This stands in sharp
contrast to the high level of clinical care and counselling provided
as part of a clinical genetic testing protocol.
In the future, PGT companies will either keep costs constant
whilst improving the quality or scope of the information conveyed
to the consumer [4] or PGT costs will decrease further, thus
possibly encouraging PGT consumer uptake or facilitating the
incorporation of elements of PGT into clinical use. Either way, it is
likely that PGT will become more accessible and potentially more
informative for a growing number of people. This will have
tangible effects on a multitude of factors such as health care
delivery and insurance [6–7]. To date, there has been no
exploration in the UK of the factors that are likely to motivate
individuals to consider PGT or the impact of PGT results on their
lifestyle and life decisions. Due to the aforementioned differences
between PGT and clinical genetic testing, findings from attitudinal
studies in clinical genetics cannot be directly transposed to PGT.
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To our knowledge this is the first survey of a large group of
unselected individuals in the UK aiming to explore interest in
PGT, the reasons people would consider taking such a test and
how they intend to use the genetic risk information provided.
Materials and Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board (Research Ethics Committee) of St
Thomas’ Hospital (approval no. EC04/015). All research subjects
provided written informed consent for the collection of data and
subsequent analysis.
Study Population
Self-completion questionnaires were sent to 6,510 active adult
twins aged from 16 years who are all volunteers on the TwinsUK
Adult Twin Registry and have responded to at least one survey in
the last four years. All were ascertained from the general
population and shown to be comparable to age-matched
population singletons. [8] These unselected monozygotic (MZ)
and dizygotic (DZ) twins have been recruited since 1992 using
twin registers and national media campaigns and have been used
in a wide variety of studies (www.twinsuk.ac.uk). For historical
reasons, the cohort is predominantly female with a mean age of 54
years (range 17–91years).
Questionnaire
The PGT questions were based on issues raised in the Harvard
University Personal Genetics Education Project [9] and questions
included in the REVEAL study of Alzheimer’s Disease. [10] These
questions were included in an 8-page questionnaire covering a
range of unrelated topics of clinical interest. Questionnaires were
sent out in autumn 2008, almost exactly one year after the
commencement of direct-to-consumer PGT and only a few
months after one company (23andMe) cut the price to $399
(approximately £250), rendering the test more affordable for a
broader range of people. Demographics such as age, gender,
family structure and socio-economic status (SES) based on
postcode were taken from either the current or earlier question-
naires. This information was used to create sub-groups in the
analysis.
The following information was given as an introduction to the
PGT-related questions:
‘‘Since 2007 it has been possible to order a personal genetic
screen over the internet. You send a sample of saliva to a
commercial company who look at selected genetic markers.
Based on these markers they estimate your personal lifetime
genetic risk of developing around 20 common diseases (such
as heart disease, Alzheimer’s disease, glaucoma or diabetes).
Results are sent via an email alert to a private web-link.’’
Firstly, subjects were asked if they were aware of such PGT
services. Then they were asked to indicate, on a 5-point Likert
scale from very likely to not at all likely (where 1= very likely, 2 =
fairly likely, 3 = undecided, 4= not very likely and 5= not at all
likely), how likely they would be to order such a test if the service
cost £250. This question was then repeated with a scenario in
which the PG test was available free-of-charge, to remove any
financial considerations. All respondents who expressed at least
some interest (i.e. codes 1,2 or 3) in taking a PG test if it was free
were then asked to what extent they agreed or disagreed with a list
of possible reasons why people may choose to take a personal
genome test.
Responses were on a 5-point Likert scale from strongly agree to
strongly disagree (where 1= strongly agree, 2 = tend to agree, 3 =
neither agree nor disagree, 4 = tend to disagree and 5= strongly
disagree). Because the number of respondents expressing disagree-
ment with any of the 5 statements was very low, the latter two
codes (4 & 5) were combined for analytical purposes.
Data Analysis
All analyses were performed using STATA 10 software.
Respondents were divided into those under and over 50 years of
age for comparison purposes, but Spearman rank correlations
were used to assess the relationship between responses and actual
age as well as between socio-economic groups. The chi-square test
statistic was used to compare differences in responses between
males and females and between those who had children and those
who were childless. In addition, a test for trend was conducted to
assess whether any observed trend between responses and the
dichotomous variables is linear and therefore amenable to useful
interpretation.
Results
4,050 twins aged between 17 and 91 completed the question-
naire. This equals a response rate of 62% (Table 1). The mean age
of respondents was 56 years, 89% were female and respondents
lived all over the UK. Non-respondents were younger on average
(mean age 50 years, range 17–91) and a slightly higher proportion
were males than females (16% compared with 11% of respondents).
The proportion of respondents in each of the socioeconomic status
(SES) groups was a fair representation of the distribution within our
cohort. Four in five respondents (79%) had children.
Interest in personal genetic testing (PGT)
The level of awareness of PGT was low with only 1 in 8 people
(13%) having heard of the service (Table 2). Younger people were
significantly more likely to be aware of PGT than older people, but
there were no other demographic differences between those who
were aware of PGT and those who were not. Level of interest in
taking such a test was clearly dependent on cost. There was very
Table 1. Respondents characteristics.
Number %
AGE * Under 50 1,144 28
Over 50 2,906 72
GENDER Female 3,624 89
Male 426 11
CHILDREN # Yes 2,935 79
No 784 21




5 (Highest 20%) 1264 35
*m= 56.4; range 17-91;
# Total less than 4,050 due to missing responses.
doi:10.1371/journal.pone.0013473.t001
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little interest expressed in ordering a personal genome test if it cost
£250; only 5% were very or fairly likely to order the test at this
price, with those of lower SES expressing the least interest
(p,0.01). However, with the scenario of PGT tests being available
at no cost, interest rose significantly, with nearly half of all
respondents (48%) saying they would be very or fairly likely to
order such a test. A further 1 in 5 (22%) were undecided; with only
3 in 10 (30%) saying they were unlikely to order a test. Younger
people and males expressed significantly more interest than older
people and females (p,0.01). Respondents in the highest SES
group were significantly less likely to order a personal genomic test
if it was a free service compared with those in lower SES groups
(p,0.02).
Reasons to undergo personal genomic testing
Attitudes to five putative reasons for taking a personal genomics
test were analysed for those respondents who had expressed at
least some interest in taking such a test if it was free (70% overall,
N= 2,814) (Table 3).
In this group, the most frequently endorsed reason for taking the
test was to ‘‘encourage me to adopt a healthier lifestyle if found to
be at high genetic risk of a disease’’. More than 9 in 10 (93%)
agreed with this statement, of whom 55% expressed strong
agreement and 38% tended to agree. There was a significant
correlation with age, with younger people more likely to endorse
this reason than older respondents (p,0.01). Females were also
significantly more likely to agree compared with males (p,0.01).
Almost as many respondents (86% overall) agreed they would take
a personal genomic test in order to ‘‘learn more about myself’’.
Again, the younger the respondents, the more likely they were to
endorse this statement (p,0.01).
Approximately 4 in 5 respondents agreed that being able to
‘‘convey genetic risk information to my children’’ and so the
‘‘doctor can monitor my health more closely’’ were reasons for
taking a personal genomic screen (80% and 79% respectively).
Older respondents were significantly more likely to endorse both
these statements than younger respondents (p,0.01), as were
females compared with males (p,0.01) and those with children
compared to those without children (87% and 49% respectively,
p,0.01). Respondents were equally divided (50% agreed and 50%
were undecided or disagreed) as to whether they would take a
personal genome test in order to ‘‘assist in financial planning for
the future’’ with only one in five (20% overall) expressing strong
agreement with this statement. As could be expected, there was a
correlation with age, with older respondents more likely to endorse
this as a reason for taking the test (p,0.01). Females and those
with children were also significantly more likely to endorse this
statement than males and those without children (p,0.02 and
p,0.01 respectively). Notably, we found no significant trends with
SES and endorsement levels of any of the five listed statements.
Discussion
Our findings suggest that at the end of 2008 awareness of PGT
among the general public was still low (13%), but this may have
increased over the past year with significantly more exposure in
the media. Not surprisingly, cost is a decisive factor in the level of
purported interest in taking such a test. The fact that only 1 in 20
(5%) expressed interest in PGT at a cost of £250 suggests uptake
will not increase dramatically as long as costs remain stable.
However, the high level of interest in a free personal genetic test
(48% said they were very or fairly likely to order PGT and 22%
were undecided) suggests that uptake may increase when costs
decrease. Graves et al [11], in a telephone survey of 105 women
with a family history of breast or ovarian cancer, also found that as
costs increased interest in SNP-based risk testing decreased, but
neither study assessed actual uptake. Although comparisons
Table 2. Interest in Personal Genetic Screening.
Total AGE GENDER CHILDREN SES (low–high)
4,050 ,50 .50 F M Yes No 1&2 3 4 5
% % % P* % % P % % P % % % % P*
Awareness of Personal Genetic Screening tests
YES 13 15 13 ,0.01 13 15 NS 13 14 NS 13 12 13 14 NS
NO 87 85 87 87 85 87 86 87 88 87 86
Likelihood of ordering test if £250
Very likely 2 1 2 NS 2 2 NS 2 2 NS 2 2 2 2 ,0.01
Fairly likely 3 3 4 3 4 3 3 3 3 4 3
Undecided 12 12 12 12 11 12 11 9 11 13 11
Not very likely 33 34 33 33 39 34 32 31 31 33 37
Not at all likely 50 51 50 50 44 49 52 55 53 49 47
Likelihood of ordering test if free
Very likely 30 35 28 ,0.01 29 37 ,0.01 30 29 NS 32 31 30 27 ,0.02
Fairly likely 18 20 17 18 23 17 19 19 17 20 17
Undecided 22 21 22 22 18 22 22 21 20 22 24
Not very likely 16 14 17 17 12 16 17 14 18 15 18
Not at all likely 14 10 16 14 11 15 13 14 14 13 15
P, p-value from chi-square test for response differences between groups; bold = significant linear trend;
P*, p-value from spearman rank correlation of actual age/SES with response;
NS, not significant; % may not add up to 100 due to rounding.
doi:10.1371/journal.pone.0013473.t002
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between countries should be treated with caution, similar
hypothetical research in Russia [12] and among US users of the
online social networking platform Facebook [13] reported similarly
high levels of interest in PGT (68% and 64% respectively).
The US-based Multiplex Initiative assessed actual uptake rates
of genetic susceptibility testing for eight common conditions in
2000 healthy individuals and found that after pre-test education,
only 14% proceeded with testing [14]. Whereas we acknowledge
that our ‘hypothetical uptake rate’ may indeed diminish in an
actual testing scenario, crucial differences between the studies
make comparisons complex. Subjects in the Multiplex Initiative
belonged to US private health care organisation, were aged
between 25 and 40, and had an educational session prior to
deciding whether to undertake testing. In contrast, our subjects
had a mean age of 56, were given only basic information on PGT
(to mimic the non-clinical aspect of DTC internet testing) and are
representative of members of the general public.
Sanderson et al [15] found that hypothetical interest only
modestly predicted actual uptake of genetic testing for lung cancer
risk. However, because the sample was small and highly selected
and as participants were all smokers related to patients with lung
cancer, results could generate high magnitudes of risk compared
with the impact of results from PGT. Nonetheless, in this study,
actual uptake was significantly higher among participants who said
they ‘‘definitely would’’ take the test compared with others (45% vs
26%, p= 0.035). To our knowledge, neither hypothetical nor
actual PGT uptake rates have been explored in the UK. We view
a hypothetical study as a crucial first step towards assessing the
public’s interest in and attitudes to PGT and believe that our
results warrant further research into actual uptake rates.
Our finding that younger people and males reported a higher
level of interest in free PGT corresponds with findings from other
studies on attitudes towards new health technologies, where older
individuals [16] and females [17] were found to be more sceptical.
Our results also suggest that for respondents in the highest SES
group, the decision about whether or not to undertake PGT may
be less influenced by cost.
Among those expressing at least some interest in PGT
(N=2,814), nearly all (93%) endorsed as a reason for taking the
test to ‘‘encourage me to adopt a healthier lifestyle if found to be at
high genetic risk of a disease’’. Similarly, the aforementioned
studies conducted in Russia and the US both reported that the vast
Table 3. Reasons to take a Personal Genetic Screen.
Total AGE GENDER CHILDREN SES (low–high)
2814 ,50 .50 F M Yes No 1&2 3 4 5
% % % P* % % P % % P % % % % P*
Encourage me to adopt a healthier lifestyle if found to be at high genetic risk of a disease
Strongly Agree 55 57 55 ,0.01 56 48 ,0.01 54 59 NS 55 57 55 53 NS
Tend to Agree 38 36 38 37 41 40 33 38 36 38 40
Neither Agree or Disagree 5 5 5 5 9 5 7 6 5 5 5
Strongly/Tend to Disagree 2 1 2 1 3 2 1 1 1 1 2
Learn more about myself
Strongly Agree 47 51 46 ,0.01 47 47 NS 46 50 NS 45 51 50 43 NS
Tend to Agree 39 36 40 39 40 40 38 41 36 37 43
Neither Agree or Disagree 11 9 12 11 11 12 10 12 11 12 11
Strongly/Tend to Disagree 3 3 2 3 2 3 2 2 2 2 3
Convey genetic risk information to my children
Strongly Agree 45 37 48 ,0.01 46 33 ,0.01 49 25 ,0.01 44 50 45 40 NS
Tend to Agree 35 34 35 34 36 38 24 32 31 36 39
Neither Agree or Disagree 15 20 13 14 22 11 34 18 14 13 15
Strongly/Tend to Disagree 6 9 4 5 9 3 18 7 4 6 5
Doctor can monitor my health more closely
Strongly Agree 39 33 41 ,0.01 40 31 ,0.01 40 33 ,0.01 40 40 38 36 NS
Tend to Agree 40 37 42 40 42 42 37 38 42 40 43
Neither Agree or Disagree 16 22 14 16 19 15 20 17 13 18 17
Strongly/Tend to Disagree 5 8 3 4 8 3 9 4 5 4 4
Assist in financial planning for the future
Strongly Agree 20 17 21 ,0.01 20 15 ,0.02 20 15 ,0.01 19 21 20 18 NS
Tend to Agree 30 26 31 29 31 31 26 29 32 27 31
Neither Agree or Disagree 35 37 34 35 33 35 35 38 32 39 33
Strongly/Tend to Disagree 15 20 14 15 21 14 23 15 15 14 18
(Base = very/fairly likely or undecided to order PG test if free);
P*, p-value from spearman rank correlation of actual age/SES with response;
P, p-value from chi-square test for response differences between groups; bold = significant linear trend;
NS, not significant; % may not add up to 100 due to rounding.
doi:10.1371/journal.pone.0013473.t003
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majority of participants felt they would modify lifestyle if found to
be at high risk for a complex disease [12,13]. Numerous studies
have investigated whether knowledge of genetic risk associated
with one or several gene variants may motivate risk reducing
behaviour - for conditions such as Alzheimer’s disease, various
cancers and obesity - due to the highly personalised nature of the
information provided. However, they do not provide conclusive
evidence of long-term behavioural change and clinical benefit
[10;18–24]. In most cases, sample sizes have been small and the
study population highly selected and non-representative of the
general population. In the case of smoking cessation studies that
disclose lung cancer susceptibility gene status to smokers (which
represents the main basis for behavioural motivation research), this
research is complicated by issues of addiction which may confound
the motivational impact of genetic risk disclosure. Furthermore, as
McBride et al [25] state in their comprehensive assessment of the
behavioural response to personalised genetic risk profiles, it is
likely that genetic risk messages are not always fully understood by
recipients.
The motivational impact of DTC testing where personal genetic
risk is based on numerous common genetic variants and is even
more probabilistic has yet to be assessed in a realistic scenario.
Hence our findings can be seen as an indicator of current
intentions of the general public and their level of awareness of
modifiable risk factors for many diseases. Further research is
needed to assess whether disclosing personalised genetic risk for
common complex diseases does indeed lead to clinically useful
behavioural changes.
As many as four in five (80%) of those respondents in our survey
who were interested in PGT endorsed as a reason for taking the
test that their ‘‘doctor can monitor my health more closely’’.
Further in-depth discussion with a subset of these individuals in
focus groups for a related research project (EL, MSc Thesis),
clearly indicated that consumers felt they would need the help of
their GP to interpret their results and to discuss subsequent
implications for their future health. In the USA, McGuire [13]
found a similar proportion of respondents (78%) would ask their
physician to help interpret the results, even if the internet company
that conducted the analysis provided help. Indeed, some PGT
companies actively encourage customers to discuss their genetic
test results with their physician, claiming that these results,
together with their medical history, family history and lifestyle
enable their doctor to take a more personal approach to
monitoring their health. These findings could have serious
implications for the UK National Health Services (NHS). Our
results suggest that - even though the predictive value of these tests
may be limited - there could be a considerable burden imposed on
GPs, both in terms of time and costs, if uptake of PGT becomes
more widespread in the future with patients requesting help from
their GP to interpret their results.
This raises two important issues. Firstly, it is imperative that
potential test-takers are educated as to the current limitations of
PGT in terms of their predictive value (non-modifiable genetic
risk) as well as the value of adopting a healthy lifestyle regardless of
genetic susceptibility. Secondly, in addition to questioning whether
interpretation of DTC PGT results should be the responsibility of
GPs, the question arises as to their level of competency to explain
results to their patients, as they are not currently trained to
interpret the results of multi-factorial disease susceptibility tests
and the clinical significance of genetic associations [26].
The UK House of Lord’s Report on Genomic Medicine 2009
[27], the US Secretary’s Advisory Committee on Genetics, Health
and Society (SACGHS) Report on Genetics Education and
Training [28], and other advisory bodies’ recommendations on
DTC genetic testing [29] have all recognised the need to train
health professionals to adequately deal with patients seeking their
help with interpreting PGT results and produce practice
guidelines. Currently confidence among GPs in the UK regarding
their expertise in genetics is reported to be low [27]. The clinical
validity (predictive value of the test results) and the clinical utility
(actionable outcomes and possibilities for prevention) of PGT is
likely to increase in the coming decade. Hence, health profession-
als in many areas of health care will need access to up-to-date
information pertaining to the scientific, ethical, regulatory, and
societal dimensions of genetic susceptibility testing for complex
diseases and conditions in order to guide their medical
management.
Our study has several limitations. The first is the question of the
generalisability of results from a twin-based cohort to the
population as a whole. Due to their participation in genetic
studies both identical and non-identical twins may be more aware
of both the genetic and environmental contributions to disease
than the general public. However, awareness of the availability of
PGT was still low in this cohort (13%) and similar high intentions
to modify lifestyle if found to be at high genetic risk of disease were
reported in two studies of non-twins previously reported [12,13].
Therefore attitudes to and expectations of PGT in our twins
appear to reflect those of singletons.
Another potential limitation is that the demographics of the
survey sample are not representative of the UK population as a
whole as, for historical reasons, the sample is predominantly
female (85%). Furthermore, as is the case for many volunteer study
cohorts, there is a higher representation of the middle and higher
social classes than the national average. Nonetheless, there were
sufficient numbers in our study for statistically significant
comparisons to be made between males and females and between
four SES groups, as well as across ages. As the twin register was
originally established as a resource for genetic research into
diseases in Caucasian populations, this precluded the inclusion of
individuals from ethnic minorities in this study. Further studies are
warranted to investigate the attitudes of ethnic minorities towards
PGT. However, this is further complicated by the fact that current
PGT algorithms for risk may not be applicable to ethnic minorities
due to differing genomic variation.
Finally, we acknowledge that the limited predictive value of
current PGT for common complex diseases was not explained in
detail to participants in our survey. However, the scenario
presented reflects the limited level of information made available
to consumers who currently take up DTC PGT over the internet
and as such, the attitudes of our respondents are relevant. We have
already stressed the importance of informing potential consumers
of issues related to the clinical utility of genetic susceptibility
testing. It remains to be seen whether uptake of PGT increases
among the general public and whether it becomes a useful clinical
tool for health professionals to improve public health. However,
our findings suggest that health care systems must prepare for the
potential ramifications of publicly-accessible genetic information
on various aspects of health care delivery.
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